Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.

Try Elite for Free

Oragenics, Inc.

Contributing Author

Recent Articles by Oragenics, Inc.

Sep-16	Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum OGEN GlobeNewswire
Aug-28	Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update OGEN GlobeNewswire
Jul-07	Oragenics Achieves Full Activation of Australian Phase IIa Trial Network - All Three Sites Now Enrolling OGEN GlobeNewswire
May-19	Oragenics to Present at Sidoti's Micro-Cap Virtual Investor Conference May 20-21 OGEN GlobeNewswire
May-18	ORAGENICS PROVIDES INVESTOR UPDATE OGEN GlobeNewswire
May-07	Oragenics Signs Letter of Intent to License CardioDialysis Technology from Sigyn Therapeutics to Target TBI-Induced Systemic Inflammation OGEN GlobeNewswire
May-05	Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. OGEN GlobeNewswire
Apr-20	Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury OGEN GlobeNewswire
Apr-13	Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury OGEN +12.95% GlobeNewswire
Mar-25	Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation OGEN OGEN -7.34% GlobeNewswire
Mar-17	ORAGENICS FILES ANNUAL REPORT ON FORM 10-K OGEN GlobeNewswire
Mar-12	ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION OGEN +8.50% GlobeNewswire
Mar-11	ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION OGEN -9.90% GlobeNewswire
Mar-10	Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia OGEN GlobeNewswire
Feb-09	Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy OGEN -5.18% GlobeNewswire
Feb-03	Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program OGEN -7.23% GlobeNewswire
Feb-02	Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care OGEN GlobeNewswire
Jan-14	Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico OGEN GlobeNewswire

Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)